Literature DB >> 16531939

Patient-delivered partner treatment for Trichomonas vaginalis infection: a randomized controlled trial.

Patricia Kissinger1, Norine Schmidt, Hamish Mohammed, Jami S Leichliter, Thomas L Gift, Bernadette Meadors, Cheryl Sanders, Thomas A Farley.   

Abstract

OBJECTIVES: Infections with Trichomonas vaginalis (TV) are common and recurrence rates are high. Better methods of treating partners of women with trichomoniasis are needed. GOAL: To determine if patient-delivered partner treatment (PDPT) is better and more cost-effective than partner referral. STUDY
DESIGN: Women attending a family planning clinic who were culture-positive and treated for TV (N = 463) were randomized to either standard partner referral (PR), booklet-enhanced partner referral (BEPR), or PDPT. At baseline and 1 month, women were interviewed and cultured for TV. Detailed cost information was also collected.
RESULTS: Most women had 1 partner, were less than 24 years old, and were black. The percentage of women reporting that their partners were treated was similar for PDPT but significantly lower for BEPR compared to PR. TV follow-up rates were similar. PDPT cost less and was cost saving compared to PR and BEPR.
CONCLUSION: Among women with TV, PDPT did not result in more partners taking the medicine or lower follow-up rates than PR but was less costly.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16531939     DOI: 10.1097/01.olq.0000204511.84485.4c

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  37 in total

1.  Patient-delivered partner treatment and Trichomonas vaginalis repeat infection among human immunodeficiency virus-infected women.

Authors:  Megan Gatski; Leandro Mena; Judy Levison; Rebecca A Clark; Harold Henderson; Norine Schmidt; Susan L Rosenthal; David H Martin; Patricia Kissinger
Journal:  Sex Transm Dis       Date:  2010-08       Impact factor: 2.830

2.  A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women.

Authors:  Patricia Kissinger; Leandro Mena; Judy Levison; Rebecca A Clark; Megan Gatski; Harold Henderson; Norine Schmidt; Susan L Rosenthal; Leann Myers; David H Martin
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12-15       Impact factor: 3.731

3.  State-level gonorrhea rates and expedited partner therapy laws: insights from time series analyses.

Authors:  K Owusu-Edusei; R Cramer; H W Chesson; T L Gift; J S Leichliter
Journal:  Public Health       Date:  2017-03-24       Impact factor: 2.427

4.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

5.  Improving Women's Health and Combatting Sexually Transmitted Infections Through Expedited Partner Therapy.

Authors:  Cornelius D Jamison; Jenell S Coleman; Okeoma Mmeje
Journal:  Obstet Gynecol       Date:  2019-03       Impact factor: 7.661

Review 6.  Partner notification.

Authors:  Catherine Mathews; Nicol Coetzee
Journal:  BMJ Clin Evid       Date:  2009-05-20

7.  Optimal Timing for Trichomonas vaginalis Test of Cure Using Nucleic Acid Amplification Testing.

Authors:  Megan Clare Craig-Kuhn; Charleigh Granade; Christina A Muzny; Barbara Van Der Pol; Rebecca Lillis; Stephanie N Taylor; Norine Schmidt; David H Martin; Patricia Kissinger
Journal:  Sex Transm Dis       Date:  2019-05       Impact factor: 2.830

8.  Innovations in sexually transmitted disease partner services.

Authors:  Matthew Hogben; Linda M Niccolai
Journal:  Curr Infect Dis Rep       Date:  2009-03       Impact factor: 3.725

Review 9.  Strategies for partner notification for sexually transmitted infections, including HIV.

Authors:  Adel Ferreira; Taryn Young; Catherine Mathews; Moleen Zunza; Nicola Low
Journal:  Cochrane Database Syst Rev       Date:  2013-10-03

Review 10.  Intravaginal practices, vaginal infections and HIV acquisition: systematic review and meta-analysis.

Authors:  Adriane Martin Hilber; Suzanna C Francis; Matthew Chersich; Pippa Scott; Shelagh Redmond; Nicole Bender; Paolo Miotti; Marleen Temmerman; Nicola Low
Journal:  PLoS One       Date:  2010-02-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.